Research Article

The effect of maternal chromium status on lipid metabolism in female elderly mice offspring and involved molecular mechanism

Qian Zhang1, Xiaofang Sun2, Xinhua Xiao1, Jia Zheng1, Ming Li1, Miao Yu1, Fan Ping1, Zhixin Wang1, Cuijuan Qi1, Tong Wang1 and Xiaojing Wang1

1Key Laboratory of Endocrinology, Translational Medicine Centre, Ministry of Health, Department of Endocrinology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing 100730, China; 2Department of Endocrinology, The Affiliated Hospital of Qingdao University, Qingdao, Shandong 266003, China

Correspondence: Xinhua Xiao (xiaoxh2014@vip.163.com)

Maternal malnutrition leads to the incidence of metabolic diseases in offspring. The purpose of this project was to examine whether maternal low chromium could disturb normal lipid metabolism in offspring, altering adipose cell differentiation and leading to the incidence of lipid metabolism diseases, including metabolic syndrome and obesity. Female C57BL mice were given a control diet (CD) or a low chromium diet (LCD) during the gestational and lactation periods. After weaning, offspring was fed with CD or LCD. The female offspring were assessed at 32 weeks of age. Fresh adipose samples from CD–CD group and LCD–CD group were collected. Genome mRNA were analysed using Affymetrix GeneChip Mouse Gene 2.0 ST Whole Transcript-based array. Differentially expressed genes (DEGs) were analysed based on gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis database. Maternal low chromium irreversibly increased offspring body weight, fat-pad weight, serum triglyceride (TG) and TNF-α. Eighty five genes increased and 109 genes reduced in the offspring adipose of the maternal low chromium group. According to KEGG pathway and String analyses, the PPAR signalling pathway may be the key controlled pathway related to the effect of maternal low chromium on female offspring. Maternal chromium status have long-term effects of lipid metabolism in female mice offspring. Normalizing offspring diet can not reverse these effects. The potential underlying mechanisms are the disturbance of the PPAR signalling pathway in adipose tissue.

Introduction

More and more studies in humans reveal that undernutrition in utero leads to the reduction in birth weight [1], long-term modification in metabolic status [2] and is considered as a risk factor for obesity [3,4]. However, most animal models in which mechanism of this relationship has been studied on the lack of macronutrients in utero only. In fact, micronutrients, including minerals, have key roles in the organ development, body function and reproduction [5].

Chromium (Cr(III)) is considered as important nutrient in keeping normal lipid metabolism, balancing appetite, inhibiting fat mass and elevating lean body mass [6]. Chromium supplementation can significantly cut down total cholesterol (TC) and low-density lipoprotein (LDL) levels in Type 2 diabetes (T2D) subjects [7-10], women with polycystic ovary syndrome [11] and high fat diet rats [12,13]. The suggested minimum daily intake of chromium is 30 μg. But, the average dietary chromium intake in adults is far below this standard in many areas [14,15]. Particularly, pregnant women and elderly
Subjects are more prone to chromium deficiency [16,17]. Because they have elevated metabolic stress and inhibited absorption ratio of chromium [18,19]. Serum chromium levels in T2D patients were half of that in control subjects. Inverse correlation of HbA1c and serum chromium concentration was also addressed [17]. Vincent, J.B. [20] reports that dietary chromium deficiency elevates serum TC. This elevation of serum TC can be relieved by chromium supplementation [20]. Long term maternal chromium insufficiency increased body fat in WNIN rat offspring and that is probably due to increased oxidative stress [21]. Moreover, the up-regulation of 11β-hydroxysteroid dehydrogenase 1 (11β-HSD1) and leptin may contribute to the elevated adiposity in these offspring.

Previous studies on chronic modification in gene expression affected by maternal low chromium usually performed a candidate gene approach, whereas this method does not assess the specificity of the modifications led by chromium deficiency in the transcriptome level of the offspring and gene networks in lipid metabolism [21]. In the present study, we have adopted a genome-wide microarray to assess the influence by maternal chromium nutrition deficiency during pregnancy on gene expression in offspring.

We hypothesized that there are key genes and molecular pathways which express differently in offspring adipose when dams are fed with different chromium diets. To induce this effect, pregnant dams were given either a control diet (CD) or a low chromium diet (LCD) from gestational day 0. We analysed 32-week old offspring adipose whole genomic expression to look for the key genes and pathways involved with metabolic disturbance from maternal LCD.

**Materials and methods**

**Animals and diets**

All experiments related to animals were followed with the Approval of the Animal Care Committee of the Peking Union Medical Hospital (permit number: MC-07-6004) and were performed strictly following the standards of the Animal Ethics Committee of the Peking Union Medical Hospital. We tried our best to minimize animal pain. Seven-week-old female and male C57BL mice (17.8 ± 1.5 g) were obtained from Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences and Peking Union Medical College (Beijing, China, SCXK-2013-0107). Mice were mated at the onset of pro-oestrous. The presence of sperm in the vaginal smear is considered as impregnation. Pregnant mice (n=16) were caged individually and kept at 22°C on a 12 h light and 12 h dark cycle. From the first day of gestation, the mice were given diets with different chromium concentration. However, all the other contents of diet were the same (n=8/group). The CD (a casein-based diet based on the American Institute of Nutrition AIN-93G diet, CD), contained 1.19 mg chromium/kg diet and the low-chromium diet (only excluded in chromium, LCD) contained 0.14 mg chromium/kg diet. Atomic absorption spectrometer (TAS986, Beijing Persee General Corporation, Beijing, China) was used to assess the content of chromium in the diet. All diets were obtained from Research Diets (New Brunswick, NJ, U.S.A.). In the present study, low-chromium diet was just excluded 90% chromium potassium sulfate from CD.

The litter size in LCD group is less than that in CD group (6.00 ± 0.76 compared with 8.50 ± 0.53, P<0.05). On the first day of the new born, the litter size in mother was randomly modified to six pup mice (three males, three females, if possible) to ensure adequate and same nutrition until the pup mice were weaned. At weaning, blood was gained from the supraorbital sinus of the mothers, after fasting overnight, to assess serum chromium levels. Pups were weaned at week 3 of lactation and remained on the diet type or transferred to another diet (Figure 1, n=8/group, one female pup from each litter was randomly assigned to the experimental groups). Food and water were provided freely. The present study focused on female offspring due to the varying phenotypic effects of maternal unbalanced nutrition on male and female offspring [22]. At 32 weeks of age, female mice (n=8 per group) were killed. The blood sample was obtained from the intraorbital retrobulbar plexus after 10 h fasting and anaesthetized (ketamine 100 mg/kg i.p. Pharmacia and Upjohn Ltd, Crawley, U.K.). The adipose tissue of the offspring was quickly collected and kept at −80°C for further analysis.

**Measurement of serum chromium level**

Serum was obtained from the dams at weaning and from the offspring at 8 months of age for chromium analysis. The serum chromium concentration was measured by atomic absorption spectrometer (Atomic Absorption Spectrophotometer, Hitachi, Japan).

**Measurement of body weight and food consumption**

Body weight was assessed at weaning for dams and at birth (day 0), weaning (day 21), and at 8 months for offspring. Food consumption was assessed at 8 months for the offspring. Food consumption was determined for each group by
weighing the total amount of food given at the start of the week and then subtracting the amount of food remaining at the end of the week. The average food consumed per mouse was then obtained by dividing by the number of mice.

**Measurement of adiposity index**

The adiposity index (AI) and the index of visceral adiposity, were computed according to Taylor and Philips [23]. For this purpose, retroperitoneal, mesenteric and ovarian fat pads were quickly excised from the offspring at the time of their killing, their fresh weights were determined and the AI was computed as equation:

$$ AI = \frac{\text{Sum of the fresh weights of the three fat deposits}}{\text{Body weight}} \times 100 $$

**Assays of biochemical parameters in offspring**

Blood samples were obtained from 8-months-old offspring. The serum leptin, adiponectin, TNF-α, IL-6 and IL-1β concentrations were measured using a commercially available ELISA kit (Abcam, Cambridge, MA, U.S.A.). All samples were analysed in duplicate and the intra-assay coefficient of variation in leptin, adiponectin, TNF-α, IL-6 and IL-1β was 4.7, 4.9, 5.3, 4.7 and 4.5% respectively. Serum TC, triglyceride (TG), HDL-C and LDL-C concentrations were determined by an enzyme end-point method using a commercial kit (Roche Diagnostics, GmbH, Mannheim, Germany).

**mRNA preparation, labelling and hybridization**

Total adipose tissue RNA was extracted using a total RNA Isolation Kit (mirVana™, Ambion, Sao Paulo, SP, Brazil). Six microarrays were performed from the CD–CD group (n=3) and LCD–CD group (n=3). Briefly, 300 µg of total RNA was reverse transcribed into cDNA. Samples were then transcribed into cRNA and labelled with the fluorescent dye Cy3 (for test sample) or Cy 5 (for reference sample). Then, the samples were hybridized to an Affymetrix GeneChip Mouse Gene 2.0 ST whole transcript-based array (Affymetrix, Santa Clara, CA, U.S.A.). This gene array includes 26515 genes. The slides were then scanned by Affymetrix GeneChip Command Console software (Affymetrix, Santa Clara, CA, U.S.A.). All data were transferred into GeneSpring version 12.5 (Agilent Technologies, Palo Alto, CA, U.S.A.) to normalize the data, control the quality and analyse. Fold change and P value (from t test) were used to identify differentially expressed genes (DEGs). The threshold was set at a fold change $\geq 1.5$ and a $P$ value $\leq 0.05$. 

---

Figure 1. Timeline of animal experiment

Time schedule of the animal experiment. Female mice received the CD or LCD during the gestational and lactation periods. The female offspring were monitored at birth, 3 weeks and 8 months of age.
Pathway and network analysis

We conducted hierarchical clustering for DEGs in the LCD–CD group compared with the CD–CD group. A heat map was constructed by compiling the DEG into TIGR MeV (MultiExperiment Viewer) software (http://www.tm4.org/) [24]. To fully clarify the biological meaning of the cluster of DEGs, gene ontology (GO) classification system and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways were analysed by DAVID (database for annotation, visualization and integrated discovery) software (http://david.abcc.ncifcrf.gov/) [25]. String software was used to draw the genetic interaction network (http://string-db.org/) [26].

Real-time PCR validation

For the analysis of the expression level of zinc finger protein (ZFP) 423 (Zfp423), lipoprotein lipase (Lpl), fatty acid binding protein 3 (Fabp3), sterol regulatory element binding transcription factor 1 (Srebf1), peroxisome proliferator activated receptor γ (Pparg) and CCAAT/enhancer-binding protein (Cebpa) in the CD–CD group and the LCD–CD group, real-time PCR was performed by using SYBR Green Master Mix. Specific primers for each gene were listed in Table 1. Reactions were performed in a total volume of 20 μl, including 5 μl cDNA (diluted 1:100), 10 μl SYBR Green Master Mix (Applied Biosystems, Foster City, CA, U.S.A.) and 2.5 μl of each specific primer (5 nM) and run in the ABI Prism 7500 real-time PCR system (Applied Biosystems, Foster City, CA, U.S.A.). The cycling conditions were set at 95°C for 10 min; 45 cycles at 95°C for 15 s and 60°C for 1 min. Gadph is measured for normalization. The ΔΔCt method was calculated to assess the relative quantifications [27].

Statistical analysis

All data are shown as mean ± S.D. ANOVA, followed by Tukey’s post hoc test and unpaired Student’s t test were used to analyse the data. Fisher’s exact test was used to perform GO and KEGG pathway analysis. *P<0.05 was considered significant. All analysis were done with GraphPad Prism Software version 5.0 (San Diego, CA, U.S.A.).

Results

Effect of LCD on body weight and serum chromium concentration in dams

Serum chromium was lower in LCD (0.45 ± 0.09 ng/ml) than in CD (0.89 ± 0.22 ng/ml) mice (*P<0.01). However, there was no difference between LCD and CD mice in the levels of body weight at weaning (23.1 ± 3.5 compared with 22.3 ± 3.4 g).

Effect of maternal LCD on serum chromium level in pups

At 32-weeks compared with the CD–CD group and LCD–CD group, serum chromium in the CD–LCD group and LCD–LCD group significantly decreased (*P<0.01). Importantly, the serum chromium level in the LCD–CD group was corrected to normal (Figure 2a).

Effect of maternal LCD on body weight and food consumption in pups

Despite comparable birth (day 0) weights and weaning (day 21) weights, body weight at 8 months of age in the CD–LCD group, LCD–LCD group and LCD–CD group was higher than in the CD–CD group (*P<0.05, Figure 2b–d), although food intake was comparable among the groups (Figure 2e).

Effect of maternal LCD on fat-pad weight in pups

Fat-pad weight in the CD–LCD, LCD–CD and LCD–LCD groups was higher than in the CD–CD group (*P<0.05, Figure 2f). Interestingly, a reverse to the CD did not normalize the fat-pad weight.
Figure 2. Metabolic indicators affected by maternal low chromium diet

Serum chromium level (a) at 8 months of age in offspring, birth weight (b), weaning weight (c), and body weight (d), food intake (e), fat pad weight (f), serum TG (g), TC (h), HDL-C (i), LDL-C (j), leptin (k), adiponectin (l), TNF-α (m), IL-6 (n) and IL-1β (o) at 8 months of age in offspring. Values are mean ± S.D. (n=8); *P<0.05, ** P<0.01.
Table 2 The most enrichment pathways affected by maternal low chromium diet by using KEGG ($P<0.001$)

| Pathway ID   | Pathway name                          | Count | Fold enrichment | $P$-value     |
|--------------|---------------------------------------|-------|-----------------|---------------|
| mmu00280     | Valine, leucine and isoleucine degradation | 12    | 16.44           | $6.45 \times 10^{-11}$ |
| mmu03320     | PPAR signalling pathway               | 11    | 8.77            | $3.22 \times 10^{-7}$  |
| mmu00561     | Glycerolipid metabolism               | 7     | 9.39            | $8.06 \times 10^{-5}$  |
| mmu00600     | Sphingolipid metabolism               | 6     | 9.00            | $4.57 \times 10^{-4}$  |
| mmu00071     | Fatty acid metabolism                 | 6     | 8.40            | $6.32 \times 10^{-4}$  |

**Effect of maternal LCD on serum lipid profile in pups**

The LCD–LCD group offspring had higher serum TC and TG ($P<0.05$, Figure 2g,h). Meanwhile, the CD–LCD group had higher TG and LDL-C ($P<0.05$, Figure 2g,i). Importantly, TG and LDL-C levels in the LCD–CD group did not return to normal (Figure 2g,j). No differences were observed in the serum HDL-C levels among the different groups (Figure 2i).

**Effect of maternal LCD on serum leptin, adiponectin and pre-inflammation cytokines in pups**

Serum leptin, TNF-α and IL-6 levels were higher in the LCD–LCD group than in the CD–CD group ($P<0.05$, Figure 2k,m,n). Serum TNF-α level was still higher in the LCD–CD group than the CD–CD group ($P<0.05$, Figure 2m). Serum adiponectin and IL-1β levels were comparable in all four groups (Figure 2l,o).

**Gene expression profile from microarray analysis**

The microarray analysis was performed from the CD–CD group (three samples) and the LCD–CD group (three samples). Hierarchical clustering analysis of the six array expression data showed a homogeneous expression profile between the samples of the two groups (Figure 3). By setting the threshold for the fold change (FC) to $\pm 1.5$ and the $P$ value at $\leq 0.05$, compared with those in the CD–CD group, we identified that the expression of 191 genes was significantly changed in the LCD–CD group (85 up-regulated, 109 down-regulated, Figure 4).

**Gene oncology, pathway and network analysis**

We analysed the microarray dataset using DAVID to look for biological pathways and functional gene groups affected by maternal LCD. We identified significant regulation of five signalling pathways, including the valine, leucine and isoleucine degradation pathway, PPAR signalling pathway, glycerolipid metabolism pathway, sphingolipid metabolism pathway and fatty acid metabolism pathway ($P<0.001$, Table 2). Altogether, 31 GO terms, including fat metabolism related GO terms, such as fatty acid metabolic process, fat cell differentiation, were significantly changed ($P<0.001$, Table 3). Figure 5 shows the classification of biological processes in GO terms. All DEGs in the PPAR pathway are shown as Figure 6.

The 191 differentially expressed DEGs were mapped using String online software (confidence score =400). We identified that 86 nodes (genes) have 215 joint edges (interactions) from these DEGs. In these nodes and edges, 13 nodes (each node with more than 10 joint edges) have 190 joint edges, representing 88% of all the nodes. These 13 nodes are ubiquitin C (Ubc), acetyl-coenzyme A carboxylase β (Acacb), FB1 osteosarcoma oncogene (Fos), Srebf1, Pparg, interleukin 6 (Il6), Lpl, acyl-CoA synthetase long-chain family member 1 (Acsl1), cyclin-dependent kinase inhibitor 1A (Cdkn1a), Cebpa, Ppard, diacylglycerol O-acyltransferase 1 (Dgat1) and hydroxyacyl-coenzyme A dehydrogenase (Hadh). They may have important functions in lipid metabolism affected by maternal low chromium in female offspring (Figure 7).

**Real-time PCR analysis**

Because network analysis showed PPARγ pathway was in the centre of all 191 DEGs in LCD–CD group compared with CD–CD group, we selected six DEGs in PPARγ pathway to perform the real-time PCR analysis. The expression of Srebf1, Lpl, Fabp3, Pparg, Cebpa and Zfp423 increased in the LCD–CD group ($P<0.05$). This result agreed with the corresponding data from the array (Figure 8).
Figure 3. Hierarchical clustering of differently expressed genes between LCD–CD group and CD–CD group

Hierarchical clustering of the 1.5-fold up-regulated and down-regulated genes. ‘Red’ indicates high relative expression; ‘green’ low relative expression.

Samples F1, F3, F7 belong to LCD–CD group; samples F85, F86 and F88 belong to CD–CD group.
Figure 4. Volcano Plot of all genes in gene array (LCD-CD group vs CD-CD group)

Volcano plot of genes in gene array. The red lines represent 1.5-fold up- and down-regulation and the blue line shows a $P$-value of 0.05. The dots in right block above the blue line are up-regulated genes; the dots in left block above the blue line are down-regulated genes.

Figure 5. GO biological process classification affected by maternal low chromium diet

The most obvious changes in GO biological process classification.
Table 3 The most enrichment GO terms affected by maternal low chromium diet (P<0.001)

| Term                                      | Count | P-value  | Fold enrichment | Catalogue               |
|-------------------------------------------|-------|----------|-----------------|-------------------------|
| Fatty acid metabolic process              | 17    | 4.21 x 10^-11 | 9.16            | Biology process         |
| Fat cell differentiation                   | 9     | 1.54 x 10^-7  | 14.63           | Biology process         |
| Brown fat cell differentiation             | 7     | 3.54 x 10^-7  | 23.94           | Biology process         |
| Glycerolipid metabolic process            | 9     | 4.52 x 10^-5  | 6.91            | Biology process         |
| Acylglycerol metabolic process             | 6     | 6.62 x 10^-5  | 13.83           | Biology process         |
| Neutral lipid metabolic process            | 6     | 8.26 x 10^-5  | 13.22           | Biology process         |
| Glycol eryth metabolic process             | 6     | 8.26 x 10^-5  | 13.22           | Biology process         |
| Coenzyme metabolic process                 | 9     | 9.37 x 10^-5  | 6.24            | Biology process         |
| Organic ether metabolic process            | 6     | 1.13 x 10^-4  | 12.39           | Biology process         |
| Response to insulin stimulus               | 6     | 3.03 x 10^-4  | 10.08           | Biology process         |
| Regulation of hormone secretion            | 5     | 4.41 x 10^-4  | 13.77           | Biology process         |
| TG metabolic process                       | 5     | 4.41 x 10^-4  | 13.77           | Biology process         |
| Cofactor metabolic process                 | 9     | 4.87 x 10^-4  | 4.90            | Biology process         |
| Regulation of fat cell differentiation     | 4     | 6.02 x 10^-4  | 23.33           | Biology process         |
| Monocarboxylic acid transport              | 4     | 8.45 x 10^-4  | 20.88           | Biology process         |
| Mitochondrial lumen                        | 14    | 6.91 x 10^-9  | 8.66            | Cellular components     |
| Mitochondrial matrix                       | 14    | 6.91 x 10^-9  | 8.66            | Cellular components     |
| Mitochondrial part                         | 23    | 6.97 x 10^-9  | 4.42            | Cellular components     |
| Mitochondrion                              | 37    | 7.61 x 10^-9  | 2.82            | Cellular components     |
| Monocarboxylic acid binding                | 7     | 1.55 x 10^-7  | 27.34           | Molecular function      |
| Cofactor binding                           | 14    | 2.01 x 10^-7  | 6.53            | Molecular function      |
| Carboxylic acid binding                    | 8     | 1.48 x 10^-6  | 9.92            | Molecular function      |
| Coenzyme binding                           | 10    | 1.97 x 10^-6  | 6.59            | Molecular function      |
| Ligase activity, forming carbon-carbon bonds| 4 | 2.77 x 10^-5  | 60.26           | Molecular function      |
| Ligase activity, forming carbon-sulfur bonds| 5 | 1.28 x 10^-4  | 18.83           | Molecular function      |
| O-Acyltransferase activity                 | 5     | 3.12 x 10^-4  | 15.06           | Molecular function      |
| Acyl-CoA dehydrogenase activity            | 4     | 4.16 x 10^-4  | 26.36           | Molecular function      |
| Acid-thiol ligase activity                 | 4     | 5.02 x 10^-4  | 24.81           | Molecular function      |
| Biotin binding                             | 3     | 8.62 x 10^-4  | 63.27           | Molecular function      |
| Fatty acid binding                         | 4     | 9.55 x 10^-4  | 20.08           | Molecular function      |
| Vitamin binding                            | 7     | 9.78 x 10^-4  | 6.10            | Molecular function      |

Discussion

In the present study, we found that the body weight of offspring from low chromium dams at birth and at 21 days did not differ from normal mice. However, at 32 weeks of age, the body weight of offspring from low chromium dams was greater than control mice. Kumar et al. [28] reported that the mice from vitamin B12-deficient mothers had reduced birth weights and increased body weights at 3 months. Additionally, maternal low chromium elevated fat-pad weight in pups at 8 months of age. A low-protein diet could increase adipocytes in offspring at 12 weeks of age [29]. Maternal Mg restriction increases body fat and decreases lean body and fat-free mass [30].

We also found that maternal low chromium increased the serum TG and LDL-C in pups at 8 months of age. Venu et al. [30] reported that the pups from Mg-restricted mothers had an increased plasma TG than control pups at 90 days. Maternal vitamin B12 restrictions increased TC (3 months and 12 months) and TG (3 months) in Wistar rat offspring [28]. Additionally, a 50% food restriction increased rat offspring serum TG [31].

Moreover, maternal low chromium increased serum leptin, TNF-α and IL-6 in the offspring at 8 months of age. A reverse diet could only correct the change in leptin and IL-6, but could not correct the change in TNF-α. Riddle et al. [32] found that intrauterine growth restriction (IUGR) increased circulating and adipose TNF-α in rat pups. Further, a maternal vitamin B12-restricted diet increased circulating and adipose tissue levels of TNF-α, leptin and IL-6 in offspring at 12 months of age [28].

Next, we performed microarray gene expression profile analysis to find the mechanism of the effect of a maternal low-chromium diet on the offspring. We found many members of the ZFP family were significantly up-regulated, such as Zfp119α and Zfp423. ZFP423 is an important transcription factor that activates adipogenic signalling. Yang et al.
[33] found that obese mothers inhibited DNA methylation and histone modification of Zfp423 promoter, enhanced Zfp423 expression and activated adipogenic differentiation in foetal mice. Overexpressed Zfp423 leads to increase the expression of PPARγ and adipogenic commitment in progenitor cells. Downexpression of Zfp423 inhibits PPARγ expression and mitigates adipogenic differentiation [34].

By using gene pathway and network analysis, we identified that the PPAR pathway was significantly affected by maternal low chromium on the female offspring. Gene array and real-time PCR results also identified that maternal low chromium increased Pparγ, Sreb, Lpl, Fabp3 and Cebpα expression in the offspring adipose. Adipogenesis involves adipocyte differentiation, lipogenesis and lipid accumulation in adipose cells [35]. PPARγ and C/EBP are transcription factors, which can activate adipocyte differentiation [36]. In particular, C/EBPs can trigger adipogenic transcription factor PPARγ to induce the expression of lipogenic transcription factor SREBP1, activate Lpl and fatty acid synthase [37,38] and lead to adipocyte differentiation [36], intracellular TGs hydrolysis and fatty acid release from adipocytes [39].

In previous studies, obese rat and human subjects have enhanced PPARγ expression in the adipose tissue [40-42]. Furthermore, PPARγ expression is related to high-fat diet. In fasting status, PPARγ expression is inhibited [43]. In particular, PPARγ expression is inhibited in obese humans with a low-calorie diet [44] and in obese rats undergoing exercise [45,46]. Desai et al. [47] found that IUGR male offspring had increased PPARγ and its co-regulators protein expression at birth and the adult period in adipose. Ahmad et al. [48] reported that vitamin B12-deficient mothers have increased hepatic PPARγ expression in 12-month-old mice. Thus, our data supported that through activating

---

**Figure 6.** PPAR signaling pathway affected by maternal low chromium diet

All the different expression genes in PPAR pathway. Red represents up-regulated; green represents down-regulated; grey represents no significant change.
Figure 7. Gene interaction networks affected by maternal low chromium diet

Interaction networks maps of DEGs. Thirteen nodes (more than 10 joint edges for each node) have total 190 joint edges, represents 88% of all the DEGs.

Figure 8. Real time PCR validation of differently expressed genes

Real time PCR result of DEGs.
Figure 9. Schematic illustration of the effect of maternal low chromium on offspring through PPARγ pathway. PPARγ serves a key part in the regulation of adipocyte differentiation, adipogenesis and lipid metabolism, which are affected by maternal LCD in offspring adipose tissue. Maternal LCD triggers offspring adipose PPARγ pathway through activating ZFP423, CCAAT/enhancer-binding protein α (CEBPα) and SREBP1. Activated PPARγ binds to retinoid X receptor (RXR), enhancing its downstream target adipogenesis enzymes (Fabp3 and Lpl) and conversely inducing SREBP1 and CEBPα to increase circulation TGs.

ZFP423, CEBP and SREBP1, maternal low chromium triggers the PPARγ pathway, increased lipogenesis, resulting in lipid accumulation in adipose and increased circulating TGs level in offspring. The chromium supplement in standard rodent diet is enough to improve lipid metabolism status (Figure 9).

Conclusions
In conclusion, our findings demonstrated that maternal LCD results in the potentially important alteration of adipose in the adult offspring mice. Furthermore, this change can not be reversed by normalizing the diet of the offspring. Our results mark a potential risk factor of maternal micronutrition in the incidence of obesity in offspring later in life. PPARγ serves a key part in the regulation of adipocyte differentiation, adipogenesis and lipid metabolism, which are affected by maternal LCD in offspring adipose tissue. Early intervention on PPARγ pathway maybe a potential strategy to modify the metabolic disturbance in offspring from low-chromium mothers.

Acknowledgements
We thank Beijing Compass Biotechnology Company for excellent technical assistance with the microarray experiments.

Author contribution
Q.Z., X.S., J.Z., T.W., C.Q., Z.W. and X.W. performed the experiments. M.Y., M.L. and F.P. analysed the data. X.X. contributed reagents/materials/analysis tools. Q.Z. wrote the paper. All authors read and approved the final manuscript.

Competing interests
The authors declare that there are no competing interests associated with the manuscript.

Funding
This work was supported by the National Natural Science Foundation of China [grant number 81170736, 81570715]; the National Natural Science Foundation for Young Scholars of China [grant number 81300649]; the China Scholarship Council Foundation [grant number 201308110443]; the PUMC Youth Fund [grant number 33320140022]; the Fundamental Research Funds for the Central Universities; and the Scientific Activities Foundation for Selected Returned Overseas Professionals of Human Resources and Social Security Ministry.
Abbreviations
AI, adiposity index; CD, control diet; C/EBP, CCAAT/enhancer-binding protein; Cebpa, CCAAT/enhancer-binding protein; DAVID, database for annotation, visualization and integrated discovery; DEG, differentially expressed genes; Fabp3, fatty acid binding protein 3; Gapdh, glyceraldehyde-3-phosphate dehydrogenase; LDL-C, low density lipoprotein-cholesterol; HbA1c, hemoglobin A1c; HDL-C, high density lipoprotein-cholesterol; GO, gene ontology; IL-1β, interleukin-1 beta; IL-6, interleukin-6; KEGG, Kyoto Encyclopedia of Genes and Genomes; LCD, low chromium diet; LDL, low-density lipoprotein; Lpl, lipoprotein lipase; PPAR, peroxisome proliferator activated receptor; Pparg, peroxi-
some proliferator activated receptor γ; Sreb1f, sterol regulatory element binding transcription factor 1; TC, total cholesterol; TG, triglyceride; T2D, type 2 diabetes; TNF-α, tumor necrosis factor alpha; ZFP, zinc finger protein; Zfp423, zinc finger protein 423.

References
1 Barker, D.J. (1994) Programming The Baby. Mothers, Babies, Disease in Later Life, BMJ Publishing Group, London
2 Desai, M., Crowther, N.J., Lucas, A. and Hales, C.N. (1996) Organ-selective growth in the offspring of protein-restricted mothers. Br. J. Nutr. 76, 591–603
3 Oken, E. and Gillman, M.W. (2003) Fetal origins of obesity. Obes. Res. 11, 496–506
4 Desai, M., Gayle, D., Babu, J. and Ross, M.G. (2005) Programmed obesity in intrauterine growth-restricted newborns: modulation by newborn nutrition. Am. J. Physiol. Regul. Integr. Comp. Physiol. 288, R91–R96
5 Sengupta, S., Bhaskar, M.V. and Haq, I. (2010) A study of micronutrient status in pregnancy. J. Indian Med. Assoc. 108, 817–822
6 Onakpoya, I., Posadzki, P. and Ernst, E. (2013) Chromium supplementation in overweight and obesity: a systematic review and meta-analysis of randomized clinical trials. Obes. Rev. 14, 496–507
7 Sharma, S., Agrawal, R.P., Choudhary, M., Jain, S., Goyal, S. and Agrawal, V. (2011) Beneficial effect of chromium supplementation on glucose, HbA1C and lipid variables in individuals with newly onset type-2 diabetes. J. Trace Elem. Med. Biol. 25, 149–153
8 Palva, A.N., Lim, J.G., Medeiros, A.C., Figueiredo, H.A., Andrade, R.L., Ururahy, M.A. et al. (2015) Beneficial effects of oral chromium picolinate supplementation on glycemic control in patients with type 2 diabetes: a randomized clinical study. J. Trace Elem. Med. Biol. 32, 66–72
9 Whittfeld, P., Perry-Strong, A., Walsh, E., Weatherall, M. and Krebs, J.D. (2016) The effect of a cinnamon-, chromium- and magnesium-formulated honey on glycemic control, weight loss and lipid parameters in type 2 diabetes: an open-label cross-over randomised controlled trial. Eur. J. Nutr. 55, 1123–1131
10 Feng, W., Zhao, T., Mao, G., Wang, W., Feng, Y., Li, F. et al. (2015) Type 2 diabetic rats on diet supplemented with chromium malate show improved glycometabolism, glycometabolism-related enzyme levels and lipid metabolism. PLoS ONE 10, e0125952
11 Jamilian, M. and Asemi, Z. (2015) Chromium supplementation and the effects on metabolic status in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial. Ann. Nutr. Metab. 67, 42–48
12 Feng, W., Mao, G., Li, Q., Wang, W., Chen, Y., Zhao, T. et al. (2015) Effects of chromium malate on glycometabolism, glycometabolism-related enzyme levels and lipid metabolism in type 2 diabetic rats: a dose-response and curative effects study. J. Diabetes Invest. 6, 396–407
13 Dodigarla, Z., Ahmad, J. and Parvez, I. (2016) Effect of chromium picolinate and melatonin either in single or in a combination in high carbohydrate diet-fed male Wistar rats. Biologiae 42, 106–114
14 Anderson, R.A. and Kozlovsky, A.S. (1985) Chromium intake, absorption and excretion of subjects consuming self-selected diets. Am. J. Clin. Nutr. 41, 1177–1183
15 Anderson, R.A. (2000) Chromium in the prevention and control of diabetes. Diabetes Metab. 26, 22–27
16 Offenbacher, E.G. and Pi-Sunyer, F.X. (1980) Beneficial effect of chromium-rich yeast on glucose tolerance and blood lipids in elderly subjects. Diabetes 29, 919–925
17 Rajendran, K., Manikandan, S., Nair, L.D., Karuthiah, R., Vijayarajan, N., Gnanasekar, R. et al. (2015) Serum chromium levels in type 2 diabetic patients and its association with glycemic control. J. Clin. Diagn. Res. 9, OC05–OC08
18 Sugii, M., Pools, N. and Yunnanakorn, A. (2014) Systematic review and meta-analysis of the efficacy and safety of chromium supplementation in diabetes. J. Clin. Pharm. Ther. 39, 292–306
19 Lefavi, R.G., Anderson, R.A., Keith, R.E., Wilson, G.D., McMillan, J.L. and Stone, M.H. (1992) Efficacy of chromium supplementation in athletes: emphasis on anabolism. Int. J. Sport Nutr. 2, 111–122
20 Vincent, J.B. (2004) Recent advances in the nutritional biochemistry of trivalent chromium. Proc. Nutr. Soc. 63, 41–47
21 Padmavathi, I.J., Rao, K.R., Venu, L., Ganesan, M., Kumar, K.A., Rao Ch, N. et al. (2010) Chronic maternal dietary chromium restriction modulates visceral adiposity: probable underlying mechanisms. Diabetes 59, 98–104
22 Aiken, C.E. and Ozanne, S.E. (2013) Sex differences in developmental programming models. Reproduction 145, R1–R13
23 Taylor, B.A. and Phillips, S.J. (1996) Detection of obesity QTLs on mouse chromosomes 1 and 7 by selective DNA pooling. Genomics 34, 389–398
24 Saeed, A.I., Bhagabati, N.K., Braisted, J.C., Liang, W., Sharov, V., Howe, R.A. et al. (2006) TM4 microarray software suite. Methods Enzymol. 411, 134–193
25 Dennis, Jr, G., Sherman, B.T., Kryw, S., Forslul, K., Heller, D., Huerta-Cepas, J. et al. (2015) STRING v10: protein–protein interaction networks, integrated over the tree of life. Nucleic Acids Res. 43, D447–D452
Livak, K.J. and Schmittgen, T.D. (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. *Methods* **25**, 402–408

Kumar, K.A., Lalitha, A., Pavithra, D., Padmavathi, I.J., Ganeshan, M., Rao, K.R. et al. (2013) Maternal dietary folate and/or vitamin B12 restrictions alter body composition (adiposity) and lipid metabolism in Wistar rat offspring. *J. Nutr. Biochem.* **24**, 25–31

Briningerl, I., Schultz, A., Rachid, T., Bomfim, M.A., Mandarim-de-Lacerda, C.A. and Aguilera, M.B. (2011) An early fish oil-enriched diet reverses biochemical, liver and adipose tissue alterations in male offspring from maternal protein restriction in mice. *J. Nutr. Biochem.* **22**, 1009–1014

Venu, L., Kishore, Y.D. and Raghunath, M. (2005) Maternal and perinatal magnesium restriction predisposes rat pups to insulin resistance and glucose intolerance. *J. Nutr.* **135**, 1353–1358

Lee, S., Lee, K.A., Choi, G.Y., Desai, M., Lee, S.H., Pang, M.G. et al. (2013) Feed restriction during pregnancy/lactation induces programmed changes in lipid, adiponectin and leptin levels with gender differences in rat offspring. *J. Matern. Fetal Neonatal Med.* **26**, 908–914

Riddle, E.S., Campbell, M.S., Lang, B.Y., Bierer, R., Wang, Y., Bagley, H.N. et al. (2014) Intrauterine growth restriction increases TNF-α and activates the unfolded protein response in male rat pups. *J. Obes.* **2014**, 829862

Yang, Q.Y., Liang, J.F., Rogers, C.J., Zhao, J.X., Zhu, M.J. and Du, M. (2013) Maternal obesity induces epigenetic modifications to facilitate Zfp423 expression and enhance adipogenic differentiation in fetal mice. *Diabetes* **62**, 3727–3735

Gupta, R.K., Arany, Z., Seale, P., Mepani, R.J., Ye, L., Conroe, H.M. et al. (2010) Transcriptional control of preadipocyte determination by Zfp423. *Nature* **464**, 619–623

Althaud, G., Grimaldi, P. and Negrel, R. (1992) Cellular and molecular aspects of adipose tissue development. *Annu. Rev. Nutr.* **12**, 207–233

Rosen, E.D., Walkey, C.J., Puigserver, P. and Spiegelman, B.M. (2000) Transcriptional regulation of adipogenesis. *Genes Dev.* **14**, 1293–1307

Fajas, L., Schoonjans, K., Gelman, L., Kim, J.B., Najib, J., Martin, G. et al. (1999) Regulation of peroxisome proliferator-activated receptor gamma expression by adipocyte differentiation and determination factor 1/sterol regulatory element binding protein 1: implications for adipocyte differentiation and metabolism. *Mol. Cell Biol.* **19**, 5495–5503

Kim, J.B. and Spiegelman, B.M. (1996) ADD1/SREBP1 promotes adipocyte differentiation and gene expression linked to fatty acid metabolism. *Genes Dev.* **10**, 1096–1107

Holm, C., Osterlund, T., Laurell, H. and Contreras, J.A. (2000) Molecular mechanisms regulating hormone-sensitive lipase and lipolysis. *Annu. Rev. Nutr.* **20**, 365–393

Tontonoz, P. and Spiegelman, B.M. (2008) Fat and beyond: the diverse biology of PPARgamma. *Annu. Rev. Biochem.* **77**, 289–312

Joss-Moore, L.A., Moore, B., Yu, X., Callaway, C.W. et al. (2010) Uteroplacental insufficiency increases visceral adiposity and visceral adipose PPARgamma2 expression in male rat offspring prior to the onset of obesity. *Early Hum. Dev.* **86**, 179–185

Janesick, A. and Blumberg, B. (2011) Minireview: PPARγ as the target of obesogens. *J. Steroid Biochem. Mol. Biol.* **127**, 4–8

Vidal-Puig, A., Jimenez-Linan, M., Lowell, B.B., Hamann, A., Hu, E., Spiegelman, B. et al. (1996) Regulation of PPAR gamma gene expression by nutrition and obesity in rodents. *J. Clin. Invest.* **97**, 2553–2561

Vidal-Puig, A.J., Considine, R.V., Jimenez-Linan, M., Werman, A., Portes, W.J., Caro, J.F. et al. (1997) Peroxisome proliferator-activated receptor gamma expression in human tissues. Effects of obesity, weight loss, and regulation by insulin and glucocorticoids. *J. Clin. Invest.* **99**, 2416–2422

Sertie, R.A., Andreotti, S., Proenca, A.R., Campana, A.B., Lima-Salgado, T.M., Batista, Jr, M.L. et al. (2013) Cessation of physical exercise changes metabolism and modifies the adipocyte cellularity of the periepididymal white adipose tissue in rats. *J. Appl. Physiol.* (1985) **115**, 394–402

Sun, C., Zeng, R., Cao, G., Song, Z., Zhang, Y. and Liu, C. (2015) Vibration training triggers brown adipocyte relative protein expression in rat white adipose tissue. *Biomed. Res. Int.* **2015**, 919401

Desai, M., Jellyman, J.K., Han, G., Lane, R.H. and Ross, M.G. (2015) Programmed regulation of rat offspring adipogenic transcription factor (PPARγ) by maternal nutrition. *J. Dev. Orig. Health Dis.* **6**, 530–538

Ahmad, S., Kumar, K.A., Basak, T., Bhardwaj, G., Yadav, D.K., Lalitha, A. et al. (2013) PPAR signaling pathway is a key modulator of liver proteome in pups born to vitamin B(12) deficient rats. *J. Proteomics* **91**, 297–308